Clinical Trial Success and Safety Risks: The success of Eledon Pharmaceuticals, Inc. depends heavily on the successful completion of its ongoing and future clinical trials for tegoprubart (AT-1501) and other potential drug candidates, as well as the demonstration of their safety and efficacy. Failure at any stage of these trials or unexpected adverse events could significantly impair the company's prospects.

Regulatory Approval Uncertainty Risks: Even if clinical trials are successful, there is no guarantee that Eledon's drug candidates, including tegoprubart, will receive the necessary regulatory approvals from agencies like the FDA in the United States or equivalent bodies internationally. The approval process is lengthy, costly, and subject to interpretation, which could delay or prevent commercialization.

Intense Competition Risks: Eledon operates in highly competitive therapeutic areas, particularly in immunology and rare diseases. Existing treatments and new products being developed by competitors, some with greater financial and human resources, could gain market share, reduce demand for Eledon's products, or lead to pricing pressures.